Yahoo Finance3d
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), asciminib; and 11 (13.8%), both medications. 1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic ...
manilatimes3d
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
Forty-six patients (57.5%) had received ponatinib; 25 (31.3%), asciminib; and 11 (13.8%), both medications. 1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic ...